Merck (NYSE:MRK) has entered a development agreement for Seattle Genetics Inc. (NASDAQ:SGEN) ladiratuzimab vedotin antibody-drug conjugate (ADC). Merck joins Gilead in investing in ADC-developer with a stake in Seattle Genetics The agreement came hours after Gilead Sciences Inc. (NYSE:GILD) announced the acquisition of Immunomedics for $21 billion. The centerpiece of Gilead’s deal is Immunomedic’s anti-Trop-2 […]
